Apple Pharmaceuticals

• Treating chronic hepatitis C virus (HCV) infection in certain patients. Ledipasvir and sofosbuvir is a combination of 2 hepatitis C virus (HCV) antiviral agents. It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.

Sofosbuvir and Ledipasvir is a combination and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver.Sofosbuvir & Ledipasvir tablets, may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer. sofosbuvir ledipasvir , ledipasvir and sofosbuvir , ledipasvir and sofosbuvir cost, ledipasvir & sofosbuvir tablets, sofosbuvir ledipasvir price.

Mechanism of action:

• Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion.
• Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase the key enzyme mediating HCV RNA replication.
• The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.

Additional Information:

• Item Code: 75997115
• Pay Mode Terms: T/T (Bank Transfer)
• Port of Dispatch: Mumbai
• Production Capacity: 2 years
• Delivery Time: Immediate
• Packaging Details: 28 Tablets in a Bottle

We are manfacturer,trader & supplier of    Resof L Tablets.
Resof L tablet should be used for both adults & pediatric patients with the age of 12 years or older or weight of at least 35kg. Used for; Genotype I, 4, 5, or 6 with compensated cirrhosis or without cirrhosis Genotype 1 infection with compensated cirrhosis or without cirrhosis Liver transplantation condition, genotype 1 with decompensated cirrhosis by use of ribavirin Genotype 1 or 4 without cirrhosis or with compensated cirrhosis by use of ribavirin Pediatric patients, HCV infection related to genotype 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis.

The usual advised dose of Resof L is one tablet should be administered as once a day. In HIV-1 co infected patients, Resof L dosage consideration is; Patient without cirrhosis: (adult or pediatric of 12 years of age or older with genotype I, IV, V or VI Chronic HCV) The prescribed dose of Resof L is one tablet should be taken orally as a single dose for 12 weeks

Without cirrhosis or compensated cirrhosis: Resof L should be taken alone as a single dose followed for 12 weeks
Therapy experienced without cirrhosis: Resof L should be taken as a single agent for once a day for 12 weeks

Therapy experienced with compensated cirrhosis: Resof L tablet should be used for 24 weeks
In decompensated cirrhosis: Resof L should be combined with ribavirin to be used, followed for 12 weeks

In liver transplantation patients with compensated cirrhosis or without cirrhosis: Resof L tablet should be combined with ribavirin for 12 weeks.
Genotype IV, V or VI :
Resof L tablets should be administered alone for 12 weeks for without cirrhosis or with compensated cirrhosis patients: On the basis of body weight the dose of ribavirin should be calculated <75kg: 1000mg; 75kg: 1200mg Ribavirin should be administered with food. Resof L should be administered with or without food.
SIDE EFFECTS 

Elevation of bilirubin Elevation of lipase Elevation of creatine kinase Severe bradycardia HBV reactivation Chest pain Dizziness Trouble in breathing Fatigue Headache Nausea Diarrhea Insomnia

Resof L Manufactured & Marketed by Dr.Reddy''s Laboratories Ltd

Additional Information:

• Pay Mode Terms: T/T (Bank Transfer)
• Port of Dispatch: Mumbai
• Production Capacity: Large
• Delivery Time: Immediate
• Packaging Details: 28 Tablets in a Bottle

• Treating chronic hepatitis C virus (HCV) infection in certain patients.
• Ledipasvir and sofosbuvir is a combination of 2 hepatitis C virus (HCV) antiviral agents.
• It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.

Sofosbuvir and Ledipasvir is a combination and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver.Sofosbuvir & Ledipasvir tablets, may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer. sofosbuvir ledipasvir , ledipasvir and sofosbuvir , ledipasvir and sofosbuvir cost, ledipasvir & sofosbuvir tablets, sofosbuvir ledipasvir price.

Mechanism of action:

• Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion.
• Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication.
• The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.

Additional Information:

• Pay Mode Terms: T/T (Bank Transfer)
• Port of Dispatch: Mumbai
• Delivery Time: Immediate

We are manfacturer,trader & supplier of  Myhep Lvir tablet. Myhep Lvir tablet should be used for both adults & pediatric patients with the age of 12 years or older or weight of at least 35kg. Used for; Genotype I, 4, 5, or 6 with compensated cirrhosis or without cirrhosis Genotype 1 infection with compensated cirrhosis or without cirrhosis Liver transplantation condition, genotype 1 with decompensated cirrhosis by use of ribavirin Genotype 1 or 4 without cirrhosis or with compensated cirrhosis by use of ribavirin Pediatric patients, HCV infection related to genotype 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis.

 Dosage and Administration

The usual advised dose of Myhep Lvir is one tablet should be administered as once a day. In HIV-1 co infected patients, Myhep Lvirdosage consideration is; Patient without cirrhosis: (adult or pediatric of 12 years of age or older with genotype I, IV, V or VI Chronic HCV) The prescribed dose of Myhep Lvir is one tablet should be taken orally as a single dose for 12 weeks

Without cirrhosis or compensated cirrhosis: Myhep Lvir should be taken alone as a single dose followed for 12 weeks
Therapy experienced without cirrhosis: Myhep Lvir should be taken as a single agent for once a day for 12 weeks

 Therapy experienced with compensated cirrhosis: Myhep Lvir tablet should be used for 24 weeks

In decompensated cirrhosis: Myhep Lvir should be combined with ribavirin to be used, followed for 12 weeks

In liver transplantation patients with compensated cirrhosis or without cirrhosis: Myhep Lvir tablet should be combined with ribavirin for 12 weeks.
Genotype IV, V or VI :
Myhep Lvir tablets should be administered alone for 12 weeks for Without cirrhosis or with compensated cirrhosis patients: On the basis of body weight the dose of ribavirin should be calculated <75kg: 1000mg; ≥75kg: 1200mg Ribavirin should be administered with food.

 Mechanism of action :

Ledipasvir is a solid prohibitor of perpetual hepatitis C viral relating non structural 5A protein which is a viral phosphoprotein. The essential part of ledipasvir in hostile to viral action instrument; Restraint of; Replication Virion assembly Secretion The mechanism of sofosbuvir associated with against viral movement is; Sofosbuvir is prohibitor of nucleotide analogue of hepatitis C viral disease identified with non basic 5B polymerase. This catalyst is in charge of interceding the HCV RNA duplication. The dynamic type of sofosbuvir is in triphosphate shape, which included diminishing the common cell uridine nucleotide and is coordinated by HCV RNA polymerase into the broadened RNA preliminary strand, which is closed in viral chain end.

 PHARMACOKINETICS

Peak plasma concentration of Myhep Lvir :
Sofosbuvir: 0.8 to 1 hour & GS331007: 3.5 to 4 hours; ledipasvir: 4 to 4.5 hours No effect produced, while Myhep Lvirshould be administered with or without food.
Plasma protein binding capacity of Myhep Lvir :
Sofosbuvir: 61 to 65% & GS-331007: minimal binding effect, ledipasvir: >99.8%
Metabolism of Myhep Lvir :
Sofosbuvir: hepatic metabolism with cathepsin A, or carboxyl esterase 1 & ledipasvir: mediated by CYP1A2, 2C8, 2C9, 2C19, 2D6 & 3A4.
Elimination of Myhep Lvir : Major route of elimination is through urine & feces. Ledipasvir through urine by 87%; sofosbuvir through urine by 80%, feces by 14% & exhaled air by 3.5%
  side effect : 

Elevation of bilirubin , lipase , creatine kinase Severe bradycardia HBV reactivation Chest pain Dizziness Trouble in breathing Fatigue Headache Nausea Diarrhea Insomnia

Additional Information:

• Pay Mode Terms: T/T (Bank Transfer)
• Port of Dispatch: Mumbai
• Delivery Time: Immediate

We are manfacturer,trader & supplier of Ledviclear tablet. Uses of Ledviclear Tablet

Ledviclear 90mg/400mg Tablet is used in the treatment of chronic hepatitis C virus (HCV) infection.

How Ledviclear Tablet works

Ledviclear 90mg/400mg Tablet is a combination of two antiviral medicines: Ledipasvir and Sofosbuvir. They work by lowering the amount of hepatitis C virus in the body and removing the virus from the blood over a period of time.

How to use Ledviclear Tablet

Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Ledviclear 90mg/400mg Tablet may be taken with or without food, but it is better to take it at a fixed time.

• Treating chronic hepatitis C virus (HCV) infection in certain patients.
• Ledipasvir and sofosbuvir is a combination of 2 hepatitis C virus (HCV) antiviral agents.
• It reduces the amount of HCV in the body by preventing the spread of the HCV within the body.

Sofosbuvir and Ledipasvir is a combination  and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver.Sofosbuvir & Ledipasvir tablets, may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer. sofosbuvir ledipasvir , ledipasvir and sofosbuvir , ledipasvir and sofosbuvir cost, ledipasvir & sofosbuvir tablets, sofosbuvir ledipasvir price.

Mechanism of action:

• Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion.
• Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication.
• The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination.

Additional Information:

• Pay Mode Terms: T/T (Bank Transfer)
• Port of Dispatch: Mumbai
• Delivery Time: Immediate